<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350454</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02306</org_study_id>
    <nct_id>NCT00350454</nct_id>
  </id_info>
  <brief_title>Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)</brief_title>
  <official_title>Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of 3 different rapamycin-eluting-stent
      platforms to reduce coronary artery reblockage after stent implantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery reblockage remains still a drawback of percutaneous coronary interventions
      even in the era of drug-eluting stents (DES). DESs working principle consists of the delivery
      of controlled amounts of antiproliferative agents at the local level, which results in the
      suppression of neointimal proliferation, the main cause of lumen re-narrowing after stent
      implantation. At present, several DES platforms have been developed and evaluated for
      clinical use. They differ between them with regard to the stent type, anti-proliferative
      drug, presence of polymers employed for drug storage and modification of drug-release
      kinetics as well as type of polymer used for this purpose. Although their mid-term efficacy
      has been well-established, there is an ongoing debate on the potential of an increased
      incidence of late stent thrombosis, particularly after discontinuation of thienopyridine
      therapy, as well as of delayed onset of restenosis or catch-up phenomenon with DESs. Based on
      animal and human pathological data, investigators have linked the above-mentioned concerns to
      the presence of polymers in DESs, which have a proinflammatory and prothrombinogenic
      potential, and sometimes may induce a hypersensitivity reaction. This trial will compare the
      anti-restenotic efficacy of the permanent polymer (PP), biodegradable polymer (BP) and
      polymer-free (PF) rapamycin-eluting stents in patients with coronary artery disease. Cypher
      stent (PP) is a stainless steel stent coated with sirolimus with use of permanent polymers
      while the ISAR stent is a rough surface stainless steel stent which allows not only polymeric
      coating (for example biodegradable polymer, BP ISAR stent) but also coating without the need
      of polymer (PF ISAR stent) in the cath lab.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-stent late luminal loss</measure>
    <time_frame>at 6 to 8-month follow-up angiogram</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-segment binary angiographic restenosis</measure>
    <time_frame>at 6 to 8-month follow-up angiogram</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of target lesion revascularization</measure>
    <time_frame>at 9-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined incidence of death or myocardial infarction</measure>
    <time_frame>at 9-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent thrombosis.</measure>
    <time_frame>at 9-month follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">605</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug eluting stent using biodegradable polymer BP stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>polymer-free drug eluting stent PF stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>permanent polymer using stents PP stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rapamycin-eluting Stent with permanent polymer</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with permanent polymer will be implanted</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rapamycin-eluting stent with biodegradable polymer</intervention_name>
    <description>due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>polymer-free, rapamycin-eluting stent</intervention_name>
    <description>due to randomization, polymer-free.rapamycin-eluting stent will be implanted</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥50% de novo stenosis located in native coronary vessels.

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

        Exclusion Criteria:

          -  Target lesion located in the left main trunk or bypass graft.

          -  In-stent restenosis.

          -  Cardiogenic shock.

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: aspirin, clopidogrel, rapamycin, stainless
             steel.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schoemig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation. 2003 May 6;107(17):2274-9. Review.</citation>
    <PMID>12732594</PMID>
  </reference>
  <reference>
    <citation>Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004 Aug 14-20;364(9434):583-91.</citation>
    <PMID>15313358</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Dibra A, Eberle S, Mehilli J, Suárez de Lezo J, Goy JJ, Ulm K, Schömig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005 Aug 17;294(7):819-25.</citation>
    <PMID>16106007</PMID>
  </reference>
  <reference>
    <citation>Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005 May 4;293(17):2126-30.</citation>
    <PMID>15870416</PMID>
  </reference>
  <reference>
    <citation>McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004 Oct 23-29;364(9444):1519-21.</citation>
    <PMID>15500897</PMID>
  </reference>
  <reference>
    <citation>Wessely R, Kastrati A, Schömig A. Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. Ann Intern Med. 2005 Sep 6;143(5):392-4. Epub 2005 Aug 16.</citation>
    <PMID>16106033</PMID>
  </reference>
  <reference>
    <citation>Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004 Feb 17;109(6):701-5. Epub 2004 Jan 26.</citation>
    <PMID>14744976</PMID>
  </reference>
  <reference>
    <citation>Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation. 2004 May 11;109(18):2168-71. Epub 2004 May 3.</citation>
    <PMID>15123533</PMID>
  </reference>
  <reference>
    <citation>Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schömig A; investigators of the individualizable durg-eluting Stent System to Abrogate Restenosis Project. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J. 2005 Aug;26(15):1475-81. Epub 2005 Jun 23.</citation>
    <PMID>15975990</PMID>
  </reference>
  <reference>
    <citation>Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schömig A; Intracoronary Stenting and Angiographic Restenosis--Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation. 2006 Jan 17;113(2):273-9. Epub 2006 Jan 3.</citation>
    <PMID>16391155</PMID>
  </reference>
  <reference>
    <citation>Wessely R, Hausleiter J, Michaelis C, Jaschke B, Vogeser M, Milz S, Behnisch B, Schratzenstaller T, Renke-Gluszko M, Stöver M, Wintermantel E, Kastrati A, Schömig A. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):748-53. Epub 2005 Jan 27. Erratum in: Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):e130.</citation>
    <PMID>15681298</PMID>
  </reference>
  <reference>
    <citation>Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005 Aug 18;353(7):663-70. Epub 2005 Aug 16.</citation>
    <PMID>16105990</PMID>
  </reference>
  <reference>
    <citation>Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2;349(14):1315-23.</citation>
    <PMID>14523139</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2006</study_first_submitted>
  <study_first_submitted_qc>July 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <last_update_submitted>January 10, 2008</last_update_submitted>
  <last_update_submitted_qc>January 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

